Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21915155 | 1.00 | KMT2A (0.38) | KMT2AAKR1B1SMN1; SMN2GAARARA | |
| SCHEMBL20997406 | 1.00 | KMT2A (0.38) | KMT2AAKR1B1SMN1; SMN2GAARARA | |
| SCHEMBL24250654 | 1.00 | KMT2A (0.38) | KMT2AAKR1B1SMN1; SMN2GAARARA | |
| SCHEMBL21625367 | 1.00 | KMT2A (0.38) | KMT2AAKR1B1SMN1; SMN2GAARARA | |
| SCHEMBL21915010 | 0.85 | KMT2A (0.39) | KMT2ASMN1; SMN2GAARARARARB | |
| SCHEMBL20997082 | 0.85 | KMT2A (0.39) | KMT2ASMN1; SMN2GAARARARARB | |
| SCHEMBL21286816 | 0.85 | KMT2A (0.39) | KMT2ASMN1; SMN2GAARARARARB | |
| SCHEMBL21625352 | 0.85 | KMT2A (0.39) | KMT2ASMN1; SMN2GAARARARARB | |
| SCHEMBL21625351 | 0.85 | KMT2A (0.39) | KMT2ASMN1; SMN2GAARARARARB | |
| SCHEMBL21625366 | 0.82 | LMNA (0.38) | KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192876-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-07 | — | — | US | disclosed |
| US-11065226-B2 | Combination comprising EP4 antagonist and immune checkpoint inhibitor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20200102284-A1 | TRICYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-04-02 | — | — | US | disclosed |
| US-20190255013-A1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192876-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | KMT2A 4069/4885AKR1B1 199/4885SMN1; SMN2 2873/4885 |
| US-20200102284-A1 | TRICYCLIC SPIRO COMPOUND | PTGER4, PTGER1, PTGER3 | KMT2A 4069/4885AKR1B1 199/4885SMN1; SMN2 2873/4885 |
| US-11065226-B2 | Combination comprising EP4 antagonist and immune checkpoint inhibitor | CD274, PTGER4, PTGER1 | KMT2A 1324/4885AKR1B1 902/4885SMN1; SMN2 4488/4885 |
| US-20190255013-A1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | CD274, PTGER4, PTGER1 | KMT2A 1324/4885AKR1B1 902/4885SMN1; SMN2 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.